Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies

Clinica Chimica Acta

Volumn 262, Issue 1-2, 1997, Pages 61-76

  Chatelut, Martine ^a   Harzer, Klaus ^b   Christomanou, Helen ^c   Feunteun, Jean ^d   Pieraggi, Marie Thérèse ^a   Paton, Barbara C ^e   Kishimoto, Yasuo ^f   O'Brien, John S ^f   Basile, Jean Pierre ^a   Thiers, Jean Claude ^a   Salvayre, Robert ^a   Levade, Thierry ^a  

^a CHU RANGUEIL   (France)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Neurochemistry/Molecular Biol Lab   (Greece)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ceramidase; Ceramide; Fibroblasts (SV40 transformed); Lysosomal storage disease; Lysosomes; Prosaposin; Saposin; Sphingomyelin

Indexed keywords

ACYLSPHINGOSINE DEACYLASE; CERAMIDE; PROSAPOSIN; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; VIRUS LARGE T ANTIGEN;

ARTICLE; CELL LINE; CELL TRANSFORMATION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DRUG DEFICIENCY; FARBER DISEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIMIAN VIRUS 40; SKIN FIBROBLAST;

SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0030915617     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(97)06527-3     Document Type: Article

References (36)

1. O'Brien JS, Kishimoto Y. Saposin, proteins: structure, function, and role in human lysosomal storage disorders. FASEB J 1991:5:301-308.
2. Fürst W, Sandhoff K. Activator proteins and topology of lysosomal sphingolipid catabolism. Biochim Biophys Ada 1992:1126:1-16.
3. Kishimoto Y, Hiraiwa M, O'Brien JS. Saposins: structure, function, distribution, and molecular genetics. J Lipid Res 1992:33:1255-1267.
4. Morimoto S, Martin BM, Kishimoto Y, O'Brien JS. Saposin, D: a sphingomyelinase activator. Biochem Biophys Res Commun 1988:156:403-410.
5. Azuma N, O'Brien JS, Moser HW, Kishimoto Y. Stimulation of acid ceramidase activity by saposin D. Arch Biochem Biophys 1994:311:354-357.
6. Klein A, Henseler M, Klein C, Suzuki K, Harzer K, Sandhoff K. Sphingolipid activator protein D (sap-D) stimulates the lysosomal degradation of ceramide in vivo. Biochem Biophys Res Commun 1994:200:1440-1448.
7. O'Brien JS, Carson GS, Seo HC, Hiraiwa M, Weiler S, Tomich JM, Barranger JA, Kahn M, Azuma N, Kishimoto Y. Identification of the neurotrophic factor sequence of prosaposin. FASEB J 1995:9:681-685.
8. Harzer K, Paton BC, Poulos A, Kustermann-Kuhn B, Roggendorf W, Grisar T, Popp M. Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses. Eur J Pediatr 1989:149:31-39.
9. Schnabel D, Schröder M, Fürst W, Klein A, Hurwitz R, Zenk T, Weber J, Harzer K, Paton BC, Poulos A, Suzuki K, Sandhoff K. Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. J Biol Chem 1992:267:3312-3315.
10. Fujita N, Suzuki K, Vanier MT, Popko B, Maeda N, Klein A, Henseler M, Sandhoff K, Nakayasu H, Suzuki K. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum Mol Genet 1996:5:711-726.
11. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961:25:585-592.
12. Moser HW. Ceramidase deficiency: Farber lipogranulomatosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th ed. McGraw-Hill: New York, 1995:2589-2599.
13. Levade T, Moser HW, Fensom AH, Harzer K, Moser AB, Salvayre R. Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells. J Neurol Sci 1995:134:108-114.
14. Gaver RC, Sweeley CC. Methods for methanolysis of sphingolipids and direct determination of long-chain bases by gas chromatography. J Am Oil Chem Soc 1965:42:294-298.
15. Jacquemin-Sablon H, Ganz L, Feunteun J. Transfer of immortality by transfection of genomic DNA from SV40 established cell lines into rat embryo fibroblasts. Biol Cell 1990:68:227-230.
16. Soeda S, Hiraiwa M, O'Brien JS, Kishimoto Y. Binding of cerebrosides and sulfatides to saposins A-D. J Biol Chem 1993:268:18519-18523.
17. Graber D, Salvayre R, Levade T. Accurate differentiation of neuronopathic and nonneuronopathic forms of Niemann-Pick disease by evaluation of the effective residual lysosomal sphingomyelinase activity in intact cells. J Neurochem 1994:63:1060-1068.
18. Levade T, Gatt S, Maret A, Salvayre R. Different pathways of uptake and degradation of sphingomyelin by lymphoblastoid cells and the potential participation of the neutral sphingomyelinase. J Biol Chem 1991:266:13519-13529.
19. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem 1985:150:76-85.
20. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957:226:497-509.
21. Levade T, Tempesta MC, Salvayre R. The in situ degradation of ceramide, a potential lipid mediator, is not completely impaired in Farber disease. FEBS Lett 1993:329:306-312.
22. Christomanou H, Harzer K. Ouchterlony double immunodiffusion method demonstrates absence of ferritin immunoreactivity in visceral organs from nine patients with Niemann-Pick disease type C. Biochem Mol Med 1996:58:176-183.
23. Christomanou H, Aignesberger A, Linke RP. Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant. Biol Chem Hoppe-Seyler 1986:367:879-890.
24. Chatelut M, Feunteun J, Harzer K, Fensom AH, Basile JP, Salvayre R, Levade T. A simple method for screening for Farber disease on cultured skin fibroblasts. Clin Chim Acta 1996:245:61-71.
25. Paton BC, Schmid B, Kustermann-Kuhn B, Poulos A, Harzer K. Additional biochemical findings in a patient and fetal sibling with a genetic defect in the sphingolipid activator protein (SAP) precursor, prosaposin. Evidence for a deficiency in SAP-1 and for a normal lysosomal neuraminidase. Biochem J 1992:285:481-488.
26. Bradova V, Smid F, Ulrich-Bott B, Roggendorf W, Paton BC, Harzer K. Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Hum Genet 1993:92:143-152.
27. Tayama M, Soeda S, Kishimoto Y, Martin BM, Callahan JW, Hiraiwa M, O'Brien JS. Effect of saposins on acid sphingomyelinase. Biochem J 1993:290:401-404.
28. Wenger DA, Sattler M, Roth S. A protein activator of galactosylceramide β-galactosidase. Biochim Biophys Acta 1982:712:639-649.
29. Furuya T, Momoi T, Suzuki Y, Sato H, Yamaguchi N. Establishment of human fibroblast cell lines with lysosomal enzyme deficiency by transformation with origin-minus SV40 DNA. J Inherit Metab Dis 1985:8:143-144.
30. Momoi T, Furuya T, Suzuki Y, Sato H, Yamaguchi N. In vitro establishment of human fibroblasts with lysosomal diseases, GM1-gangliosidosis and Sandhoff disease, by transformation with origin-minus SV40 DNA. Biosci Rep 1985:5:267-273.
31. Fowler ML, Fan YS, Mueller OT, Henry WM, Shows TB. Correction of Mucolipidosis III in vitro by gene transfer. Genomics 1993:18:236-243.
32. Yamamoto T, Ohashi T, Tokoro T, Maekawa K, Eto Y. Type C Niemann-Pick disease fibroblasts and their transformed cell lines are hypersensitive to HMG-CoA reductase inhibitors. J Inherit Metab Dis 1994:17:718-723.
33. Poulos A, Ranieri E, Shankaran P, Callahan JW. Studies on the activation of the enzymatic hydrolysis of sphingomyelin liposomes. Biochim Biophys Acta 1984:793:141-148.
34. Christomanou H, Kleinschmidt T. Isolation of two forms of an activator protein for the enzymic sphingomyelin degradation from human Gaucher spleen. Biol Chem Hoppe-Seyler 1985:366:245-256.
35. Paton BC, Hughes JL, Harzer K, Poulos A. Immunocytochemical localization of sphingolipid activator protein 2 (SAP-2) in normal and SAP-deficient fibroblasts. Eur J Cell Biol 1990:51:157-164.
36. Sandhoff K, Kolter T. Topology of glycosphingolipid degradation. Trends Cell Biol 1996:6:98-103.